Nutraceuticals as an important part of combination therapy in dyslipidaemia

Current Pharmaceutical Design

Volumn 23, Issue 17, 2017, Pages 2496-2503

  Patti, Angelo M ^a,b   Toth, Peter P ^c,d,e   Giglio, Rosaria V ^a,b   Banach, Maciej ^f   Noto, Marcello ^a   Nikolic, Dragana ^a,b   Montalto, Giuseppe ^a   Rizzo, Manfredi ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c CGH Medical Center   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular risk; Carotid; Dyslipidaemia; Endothelial dysfunction; Intima media thickness; Low density lipoprotein cholesterol; Nutraceuticals

Indexed keywords

ALPHA TOCOTRIENOL; BERBERINE; BERGAMOT OIL; CASEIN; CHLOROGENIC ACID; CHOLESTIN; CITRININ; DAIDZEIN; FISH OIL; GENISTEIN; GLYCITEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOFLAVONE DERIVATIVE; ISPAGULA; LOW DENSITY LIPOPROTEIN RECEPTOR; MANNAN; MEVINOLIN; MONACOLIN L; NUTRACEUTICAL; PECTIN; PHYTOSTEROL; PLACEBO; PLANT PROTEIN; POLICOSANOL; POLYPHENOL; POMEGRANATE EXTRACT; PRAVASTATIN; SILYMARIN; SOYBEAN PROTEIN; UNINDEXED DRUG; LIPID;

ABDOMINAL DISTENSION; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONSTIPATION; DIARRHEA; DIETARY FIBER; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPID OXIDATION; MEDITERRANEAN DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PLANT FIBER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; BLOOD; COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT;

DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; LIPIDS;

EID: 85016826285     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170317145851     Document Type: Review

References (116)

1. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-7.
2. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 1-12.
3. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3-46.
4. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
5. Banach M, Rizzo M, Toth PP, et al. Statin intolerance-an attempt at a unified definition. position paper from an international lipid expert panel. Arch Med Sci 2015; 11: 1-23.
6. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J 2015; 36: 1012-22.
7. http: //www.fimdefelice.org/p2385.html
8. Rimm EB, Ascherio A, Giovannucci E, et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996; 275: 447-51.
9. Jacobs DR, Pereira MA, Meyer KA, et al. Fiber from whole grains, but not refined grains, is inversely associated with all-cause mortality in older women: the Iowa women's health study. J Am Coll Nutr 2000; 19(3 Suppl): S326-330.
10. Estruch R, Martínez-González MA, Corella D, et al. PREDIMED Study Investigators. Effects of dietary fibre intake on risk factors for cardiovascular disease in subjects at high risk. J Epidemiol Community Health 2009; 63: 582-8.
11. Patti AM, Katsiki N, Nikolic D, et al. Nutraceuticals in lipidlowering treatment: a narrative review on the role of chitosan. Angiology 2015; 66: 416-21.
12. Anderson JW, Allgood LD, Lawrence A, et al. Cholesterollowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr 2000; 71: 472-9.
13. O'Neill FH, Sanders TA, Thompson GR. Comparison of efficacy of plant stanol ester and sterol ester: short-term and longer-term studies. Am J Cardiol 2005; 96: 29D-36D.
14. Jenkins DJ, Kendall CW, Marchie A, et al. The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metabolism 2003; 52: 1478-83.
15. Vuksan V, Sievenpiper JL, Xu Z, et al. Konjac-Mannan and American ginseng: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr 2001; 20(5 Suppl): S370-80.
16. Yoshida M, Vanstone CA, Parsons WD, et al. Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes. Eur J Clin Nutr 2006; 60: 529-37.
17. Sirtori CR, Triolo M, Bosisio R, et al. Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals. Br J Nutr 2012; 107: 1176-83.
18. Sirtori CR, Galli C, Anderson JW, et al. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: Focus on dietary proteins. Atherosclerosis 2009; 203: 8-17.
19. Anderson JW, Story L, Sieling B, et al. Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am J Clin Nutr 1984; 40: 1146-55.
20. Anderson JW, Gustafson NJ, Spencer DB, et al. Serum lipid response of hypercholesterolemic men to single and divided doses of canned beans. Am J Clin Nutr 1990; 51: 1013-9.
21. Ling WH, Jones PJ. Dietary phytosterols: a review of metabolism, benefits and side effects. Life Sci 1995; 57: 195-206.
22. Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther 2010; 28: 202-15.
23. Mannarino E, Pirro M, Cortese C, et al. Effects of a phytosterolenriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: a multicenter Italian study. Nutr Metab Cardiovasc Dis 2009; 19: 84-90.
24. Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol estercontaining margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Am J Clin Nutr 1999; 69: 403-10.
25. Amir Shaghaghi M, Abumweis SS, Jones PJ. Cholesterol-lowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis. J Acad Nutr Diet 2013; 113: 1494-503.
26. Miksicek RJ. Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med 1995; 208: 44-50.
27. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333: 276-82.
28. Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113: 1034-44.
29. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr 2003; 57: 940-6.
30. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs. lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290: 502-10.
31. Kokubo Y, Iso H, Ishihara J, et al. Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Centerbased (JPHC) study cohort I. Circulation 2007; 116: 2553-62.
32. Cicero AF, Fiorito A, Panourgia MP, et al. Effects of a new soy/beta-sitosterol supplement on plasma lipids in moderately hypercholesterolemic subjects. J Am Diet Assoc 2002; 102: 1807-11.
33. Feuerstein JS, Bjerke WS. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. J Diet Suppl 2012; 9: 110-5.
34. Ogier N, Amiot MJ, Georgé S, et al. LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur J Nutr 2013; 52: 547-57.
35. Trimarco B, Benvenuti C, Rozza F, et al. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab 2011; 4: 133-9.
36. Ruscica M, Gomaraschi M, Mombelli G, et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol 2014; 8: 61-8.
37. Cicero AF, Rosticci M, Parini A, et al. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutr J 2015; 14: 30.
38. Vasanthi HR, Parameswari RP, Das DK. Multifaceted role of tocotrienols in cardioprotection supports their structure: function relation. Genes Nutr 2012; 7: 19-28.
39. Derosa G, Bonaventura A, Bianchi L, et al. A randomized, placebocontrolled study on the effects of a nutraceutical combination of red yeast rice, Silybum marianum and octasanol on lipid profile, endothelial and inflammatory parameters. J Biol Regul Homeost Agents 2014; 28: 317-24.
40. Derosa G, Bonaventura A, Bianchi L, et al. Berberis aristata/ Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther 2013; 13: 1495-506.
41. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
42. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002; 50: 3337-40.
43. Sahebkar A, Serban C, Ursoniu S, et al. Lipid and blood pressure meta-analysis Collaboration Group. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2015; 189: 47-55.
44. Cicero AF, Brancaleoni M, Laghi L, et al. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med 2005; 13: 273-8.
45. Banerjee SK, Maulik SK. Effect of garlic on cardiovascular disorders: a review. Nutr J 2002; 1: 4.
46. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30: 785-807.
47. Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. Am J Clin Nutr 1997; 65: 445-50.
48. Cicero AF, Gaddi A. Rice bran oil and gamma-oryzanol in the treatment of hyperlipoproteinaemias and other conditions. Phytother Res 2001; 15: 277-89.
49. Scavariello EM, Arellano DB. Gamma-oryzanol: an important component in rice brain oil. Arch Latinoam Nutr 1998; 48: 7-12.
50. Berger A, Rein D, Schäfer A, et al. Similar cholesterol-lowering properties of rice bran oil, with varied gamma-oryzanol, in mildly hypercholesterolemic men. Eur J Nutr 2005; 44: 163-73.
51. Giglio RV, Patti AM, Nikolic D, et al. The effect of bergamot on dyslipidemia. Phytomedicine 2016; 23: 1175-81.
52. Toth PP, Patti AM, Nikolic D, et al. Bergamot reduces plasma lipids, Atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: A 6 months prospective study. Front Pharmacol 2016; 6: 299.
53. Jeyam M, Syed Abuthakir M, Ravikumar P, Ilanagai M. Identification of HMG CoA reductase inhibitor from nutraceuticals for atherosclerosis. Indian Res J Pharmacy Sci 2014; 1: 99-107.
54. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999; 69: 231-6.
55. Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012; 12: 1113-24.
56. Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens (Greenwich) 2012; 14: 121-32.
57. Menéndez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001; 32: 8-12.
58. Janikula M. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 2002; 7: 203-17.
59. Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006; 295: 2262-9.
60. Cubeddu LX, Cubeddu RJ, Heimowitz T, et al. Comparative lipidlowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J 2006; 152: 982.
61. Dulin MF, Hatcher LF, Sasser HC, et al. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr 2006; 84: 1543-8.
62. McCarty MF. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses 2002; 58: 487-90.
63. Patch CS, Tapsell LC, Williams PG, et al. Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. Vasc Health Risk Manag 2006; 2: 157-62.
64. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006; 47: 1281-8.
65. Solá R, Fitó M, Estruch R, et al. Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial. Atherosclerosis 2011; 218: 174-80.
66. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999; 69: 30-42.
67. Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr 1995; 125(3 Suppl): S606-611.
68. Ho SS, Pal S. Margarine phytosterols decrease the secretion of atherogenic lipoproteins from HepG2 liver and Caco2 intestinal cells. Atherosclerosis 2005; 182: 29-36.
69. Sabeva NS, McPhaul CM, Li X, et al. Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. J Nutr Biochem 2011; 22: 777-83.
70. Scichilone N, Rizzo M, Benfante A, et al. Serum low density lipoprotein subclasses in asthma. Respir Med 2013; 107: 1866-72.
71. Rizzo M, Giglio RV, Nikolic D, et al. Effects of chitosan on plasma lipids and lipoproteins: A 4-month prospective pilot study. Angiology 2014; 65: 538-42.
72. Berneis K, Rizzo M, Berthold HK, et al. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: A randomized trial. Eur Heart J 2010; 31: 1633-9.
73. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-2.
74. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
75. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99: 1-14.
76. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? Int J Cardiol 2006; 107: 166-70.
77. Björkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 416-21.
78. Shrestha S, Volek JS, Udani J, et al. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr 2006; 136: 2492-7.
79. Shrestha S, Freake HC, McGrane MM, et al. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr 2007; 137: 1165-70.
80. Lerman RH, Minich DM, Darland G, et al. Subjects with elevated LDL cholesterol and metabolic syndrome benefit from supplementation with soy protein, phytosterols, hops rho iso-alpha acids, and Acacia nilotica proanthocyanidins. J Clin Lipidol 2010; 4: 59-68.
81. Mollace, V, Sacco I, Janda E, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia 2011; 82: 309-16.
82. Gliozzi M, Carresi C, Musolino V, et al. The effect of bergamotderived polyphenolic fraction on ldl small dense particles and non alcoholic fatty liver disease in patients with metabolic syndrome. Adv Biol Chem 2014; 4: 129-37.
83. Gliozzi M, Walker R, Muscoli S, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol 2013; 170: 140-5.
84. O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med 1999; 340: 14-22.
85. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
86. Graham I, Atar D, Borch-Johnsen K, et al. European association for cardiovascular prevention and rehabilitation (EACPR). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007; 14: 1-40.
87. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-62.
88. Affuso F, Ruvolo A, Micillo F, et al. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebocontrolled study. Nutr Metab Cardiovasc Dis 2010; 20: 656-61.
89. Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92: 1189-96.
90. Murie-Fernandez M, Irimia P, Toledo E, et al. Carotid intimamedia thickness changes with Mediterranean diet: a randomized trial (PREDIMED-Navarra). Atherosclerosis 2011; 219: 158-62.
91. Mozaffarian D, Wilson PWF, Kannel WB. Beyond established and novel risk factors Lifestyle risk factors for cardiovascular disease. Circulation 2008; 117: 3031-8.
92. Nettleton JA, Schulze MB, Jiang R, et al. A priori-defined dietary patterns and markers of cardiovascular disease risk in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2008; 88: 185-94.
93. Agewall S, Fagerberg B, Berglund G, et al. Risk Factor Intervention Study Group, Sweden Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up. J Intern Med 2001; 249: 305-14.
94. Accinni R, Rosina M, Bamonti F, et al. Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. Nutr Metab Cardiovasc Dis 2006; 16: 121-7.
95. Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232: 346-60.
96. Wang P, Chen YM, He LP, et al. Association of natural intake of dietary plant sterols with carotid intima-media thickness and blood lipids in Chinese adults: a cross section study. PLoS One 2012; 7: 32736.
97. Raitakari OT, Salo P, Gylling H, et al. Plant stanol ester consumption and arterial elasticity and endothelial function. Br J Nutr 2008; 100: 603-8.
98. Raitakari OT, Salo P, Ahotupa M. Carotid artery compliance in users of plant stanol ester margarine. Eur J Clin Nutr 2008; 62: 218-24.
99. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004; 23: 423-33.
100. Gil MI, Tomas-Barberan FA, Hess-Pierce B, et al. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000; 10: 4581-9.
101. Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications of LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000; 71: 1062-76.
102. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
103. Gianetti J, Pedrinelli R, Petrucci R, et al. Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis. Am Heart J 2002; 143: 467-74.
104. Davidson MH, Maki KC, Dicklin MR, et al. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol 2009; 104: 936-42.
105. Hodis HN, Mack WJ, LaBree L, et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002; 106: 1453-9.
106. Katsiki N, Manes C. Is there a role for supplemented antioxidants in the prevention of atherosclerosis? Clin Nutr 2009; 28: 3-9.
107. Ozkanlar S, Akcay F. Antioxidant vitamins in atherosclerosis— animal experiments and clinical studies. Adv Clin Exp Med 2012; 21: 115-23.
108. Debreceni B, Debreceni L. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther 2012; 30: 227-33.
109. Salonen RM, Nyyssönen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003; 107: 947-53.
110. Plat J, Mensink RP. Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis 2000; 148: 101-12.
111. Glade MJ. Food, nutrition, and the prevention of cancer: a global perspective. American institute for cancer research/world cancer research fund, american institute for cancer research, 1997. Nutrition 1999; 15: 523-6.
112. Heber D, Lembertas A, Lu QY, et al. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001; 7: 133-9.
113. Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev 2003; 16: 497-516.
114. Marazzi G, Cacciotti L, Pelliccia F, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 2011; 28: 1105-13.
115. Dong H, Zhao Y, Zhao L, et al. The effects of berberine on blood lipids: A systematic review and meta-analysis of randomized controlled trials. Planta Med 2013; 79: 437-46.
116. Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterollowering agents. A single blind clinical investigation. Arzneimittelforschung 2007; 57: 26-30.